Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Diagnostics chain operating pathology labs, collection centres and a national reference lab in Delhi, offering routine and specialized testing (biochemistry, histopathology, genomics) to patients, hospitals and corporates. Strongest in North India, it expanded west via the Suburban Diagnostics acquisition (Mumbai). Revenue is driven by patient volumes and bundled test packages (Swasthfit); the industry is competitive with online discounters pressuring pricing.
One of India's two largest listed diagnostic chains by revenue, alongside Metropolis, with leadership in the North Indian market.
Dr. Lal Path Labs Ltd. is a constituent of NIFTY 500, NIFTY SMALLCAP 100, NIFTY SMALLCAP 250, NIFTY SMALLCAP 50. See where it sits on the market heatmap →
Consolidated annual figures taken from Dr. Lal Path Labs Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
Per-share figures are not restated. Shares outstanding changed from 8.36 crore to 16.76 crore in FY26, consistent with a bonus issue or stock split. Each year's EPS and book value below are as that year was filed, on that year's share count — so the per-share line falls across FY26 even where profit did not. Compare the absolute figures (EBITDA, free cash flow, total debt) and the margins across that boundary, not the per-share ones.
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 30.24 | 58.48 | 43.05 |
| Book value / share (₹) | 151.63 | 263.94 | 225.80 |
| Return on equity | 19.9% | 22.1% | 19.0% |
| Return on capital employed | 23.0% | 23.9% | 23.4% |
| Operating margin | 22.5% | 22.5% | 20.9% |
| Net margin | 18.4% | 20.0% | 16.3% |
| EBITDA | ₹783 Cr | ₹696 Cr | ₹609 Cr |
| Free cash flow | ₹462 Cr | ₹515 Cr | ₹478 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹83 Cr |
| Debt to equity | 0.00 | 0.00 | 0.04 |
| Interest coverage | 27.2 | 24.8 | 15.8 |
| Current ratio | 3.48 | 3.39 | 2.42 |
| Shares outstanding | 16,76,00,000 | 8,36,00,000 | 8,35,00,000 |
Open the full income statement, balance sheet and cash flow for LALPATHLAB →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.